AI Article Synopsis
- The study aimed to compare the reliability of umbilical cord blood (UCB) for complete blood count (CBC) and blood cultures with those taken from the infant's peripheral blood for group B streptococcal (GBS) sepsis screening.
- A total of 200 neonates at risk for GBS infection were involved, with samples collected from both UCB and peripheral sites after birth.
- Results showed similar CBC counts between the two sources, with a slight difference in leukopenia rates, and UCB samples had low contamination, indicating that UCB can be effectively used for GBS screening.
Article Abstract
Objective: To evaluate reliability of umbilical cord blood (UCB) for complete blood count (CBC) and blood cultures compared with the infant's blood from peripheral site for group B streptococcal (GBS) sepsis screening.
Methods: A total of 200 neonates, at risk for GBS infection, were studied prospectively. After birth, UCB sample was obtained for CBC and blood cultures from umbilical vein. Peripheral arterial/venous blood was obtained from the neonate.
Results: In 200 neonates, CBC counts were similar for clinical significance except for leukopenia (6% in UCB vs 1.2% in peripheral blood, P = .02). One UCB sample grew GBS and another grew microaerophilic streptococcus, a contaminant. A neonatal sample grew Escherichia coli, a pathogen and another neonatal sample grew Staphylococcus auricularis, a contaminant.
Conclusion: CBC results were similar from UCB and the infant for the purpose of GBS screening. Contamination of UCB sample for culture is uncommon. Hence, UCB may be used for GBS sepsis screen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0009922811431882 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial.
BMJ Open
January 2025
Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
Introduction: Omalizumab, an anti-IgE monoclonal antibody, is effective in treating antihistamine-refractory chronic spontaneous urticaria (CSU). However, tapering strategies for omalizumab are currently not well-studied, and patients may be treated longer than needed. Here, we present the rationale and design of the EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria trial, a multicentre, randomised, open-label, non-inferiority clinical trial.
View Article and Find Full Text PDFIdentification and Management of CKD-Associated Pruritus: Current Insights.
Int J Nephrol Renovasc Dis
December 2024
Department of Dermato-Venereology, 4th Military Hospital, Wroclaw, 53-114, Poland.
Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers.
View Article and Find Full Text PDFCritical review of aging clocks and factors that may influence the pace of aging.
Front Aging
December 2024
Integrative Research Institute, Sacramento, CA, United States.
Background And Objectives: Aging clocks are computational models designed to measure biological age and aging rate based on age-related markers including epigenetic, proteomic, and immunomic changes, gut and skin microbiota, among others. In this narrative review, we aim to discuss the currently available aging clocks, ranging from epigenetic aging clocks to visual skin aging clocks.
Methods: We performed a literature search on PubMed/MEDLINE databases with keywords including: "aging clock," "aging," "biological age," "chronological age," "epigenetic," "proteomic," "microbiome," "telomere," "metabolic," "inflammation," "glycomic," "lifestyle," "nutrition," "diet," "exercise," "psychosocial," and "technology.
Expanded and independent validation of the NoMoFA scale for Parkinson's disease: the Italian version.
J Neurol
December 2024
Department of Neurosciences Rita Levi Montalcini, University of Turin, Turin, Italy.
Introduction: Non-motor symptoms (NMS) in Parkinson's disease (PD) can fluctuate daily, impacting patient quality of life. The Non-Motor Fluctuation Assessment (NoMoFA) Questionnaire, a recently validated tool, quantifies NMS fluctuations during ON- and OFF-medication states. Our study aimed to validate the Italian version of NoMoFA, comparing its results to the original validation and further exploring its clinimetric properties.
View Article and Find Full Text PDFEx vivo imaging-based high content phenotyping of patients with rheumatoid arthritis.
EBioMedicine
December 2024
CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Centre for Physiology and Pharmacology, Medical University of Vienna; Vienna, Austria. Electronic address:
Background: High content imaging-based functional precision medicine approaches have been developed and successfully applied in the field of haemato-oncology. For rheumatoid arthritis (RA), treatment selection is still based on a trial-and-error principle, and biomarkers for patient stratification and drug response prediction are needed.
Methods: A high content, high throughput microscopy-based phenotyping pipeline for peripheral blood mononuclear cells (PBMCs) was developed, allowing for the quantification of cell type frequencies, cell type specific morphology and intercellular interactions from patients with RA (n = 65) and healthy controls (HC, n = 33).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!